← All trials
NCT02104817
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 30, 2014
- Primary completion
- Nov 29, 2019
- Completion date
- Nov 29, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 12792
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- AstraZenecaLead sponsor
- University of RochesterOverall official - principal investigator
- Adelaide Clinical ResearchOverall official - principal investigator
- IQVIACollaborator
- University of RochesterCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.